NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Receives Average Rating of “Hold” from Brokerages

Shares of NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) have earned a consensus recommendation of “Hold” from the five brokerages that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $11.6667.

Several analysts have issued reports on the company. Weiss Ratings lowered NeuroOne Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, May 11th. LADENBURG THALM/SH SH increased their price target on NeuroOne Medical Technologies from $1.60 to $8.00 and gave the stock a “buy” rating in a research note on Wednesday, May 13th. Finally, Zacks Research lowered NeuroOne Medical Technologies from a “strong-buy” rating to a “hold” rating in a report on Friday, March 13th.

NeuroOne Medical Technologies Price Performance

NeuroOne Medical Technologies stock opened at $3.00 on Friday. The firm has a 50 day moving average price of $3.80 and a 200-day moving average price of $4.38. NeuroOne Medical Technologies has a twelve month low of $2.89 and a twelve month high of $6.96. The company has a market capitalization of $26.10 million, a P/E ratio of -3.53 and a beta of 0.54.

NeuroOne Medical Technologies (NASDAQ:NMTC) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). NeuroOne Medical Technologies had a negative return on equity of 99.43% and a negative net margin of 68.35%.The company had revenue of $1.86 million during the quarter, compared to the consensus estimate of $2.58 million. Equities analysts expect that NeuroOne Medical Technologies will post -0.36 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Mark Christianson sold 10,000 shares of NeuroOne Medical Technologies stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $3.18, for a total value of $31,800.00. Following the completion of the transaction, the director owned 20,692 shares in the company, valued at $65,800.56. This trade represents a 32.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 11.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of NMTC. Legato Capital Management LLC bought a new stake in NeuroOne Medical Technologies during the 4th quarter valued at $34,000. Squarepoint Ops LLC purchased a new position in shares of NeuroOne Medical Technologies in the fourth quarter valued at $36,000. Susquehanna International Group LLP bought a new stake in shares of NeuroOne Medical Technologies during the 3rd quarter valued at $47,000. XTX Topco Ltd raised its stake in shares of NeuroOne Medical Technologies by 321.1% during the 4th quarter. XTX Topco Ltd now owns 85,454 shares of the company’s stock valued at $65,000 after purchasing an additional 65,163 shares during the period. Finally, Renaissance Technologies LLC lifted its holdings in NeuroOne Medical Technologies by 10.2% during the 4th quarter. Renaissance Technologies LLC now owns 763,028 shares of the company’s stock worth $578,000 after purchasing an additional 70,428 shares in the last quarter. 16.07% of the stock is owned by institutional investors.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.